The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.
The identification and subsequent optimisation of a selective non-peptidic NPY Y2 antagonist series is described. This led to the development of amine 2, a selective, soluble NPY Y2 receptor antagonist with enhanced CNS exposure.